Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Pharma (REGN) PT Raised to $472 at Goldman Sachs
August 4, 2017 7:00 AM EDTGoldman Sachs raised its price target on Regeneron Pharma (NASDAQ: REGN) to $472.00 (from $469.00) while maintaining a Neutral rating.
... MoreRegeneron Pharma (REGN) PT Raised to $455 at JPMorgan
August 4, 2017 6:58 AM EDTJPMorgan raised its price target on Regeneron Pharma (NASDAQ: REGN) to $455.00 (from $427.00) while maintaining a Neutral rating.
... MoreRegeneron Pharma (REGN) PT Raised to $580 at Leerink Partners
August 4, 2017 6:55 AM EDTLeerink Partners raised its price target on Regeneron Pharma (NASDAQ: REGN) to $580.00 (from $573.00) while maintaining a Outperform rating.
... MoreRegeneron Pharma (REGN) PT Raised to $575 at Citi
August 4, 2017 6:53 AM EDTCiti raised its price target on Regeneron Pharma (NASDAQ: REGN) to $575.00 (from $555.00) while maintaining a Buy rating.
... More